Yes, in two forms, with different numbers attached to each. Orforglipron, a small-molecule tablet, won US approval in April 2026 after a trial in which the top dose cut weight 11.2% against 2.1% on placebo [3]. Oral semaglutide, a peptide tablet that needs an absorption enhancer and an empty stomach, is not yet approved for weight loss but produced 13.6% in its own 71-week trial [5]. Neither number can be set directly against the other — different trials, different populations — and neither is what most sellers mean when they advertise "the oral option."
When this site last covered orforglipron in a pill without a needle, it was a drug in development. It is now approved in the United States for long-term weight management, alongside reduced calorie intake and increased activity [1].
What makes it different is chemical rather than clinical. Semaglutide and tirzepatide are peptides, which is why they are injected and why the oral semaglutide tablet needs an absorption enhancer and an empty stomach. Orforglipron is a small molecule, so it can be swallowed like an ordinary tablet without those constraints.
On safety at scale, the most substantial evidence so far is a pooled analysis of seven phase 3 trials covering 11,220 participants for up to 104 weeks [2]. Liver enzymes fell on average rather than rose, and categorical elevations were balanced against comparators. Six participants on orforglipron and six on comparators hit the laboratory threshold that triggers a drug-induced liver injury assessment. All six orforglipron cases had an alternative explanation, and none met Hy’s Law.
What orforglipron's own trial found
Approval rests on ATTAIN-1, a 72-week trial in 3,127 adults with obesity and no diabetes[3]. On the 36 mg dose, weight fell 11.2% against 2.1% on placebo. More than half the group on that dose, 54.6%, lost at least 10% of their body weight. Adverse events led 5.3% to 10.3% of the drug groups to stop, against 2.7% on placebo — mostly gastrointestinal, and mild to moderate. No trial has yet put orforglipron head to head against an injected GLP-1, so any comparison across separate studies is an eyeball, not a result. The full trial detail is in the ATTAIN-1 breakdown.
The other pill: oral semaglutide
Oral semaglutide is a different chemical problem with a different answer. It is a peptide, not a small molecule, so the tablet needs an absorption enhancer called SNAC and an empty stomach to work at all. Absolute bioavailability runs about 0.4% to 1% under fasting conditions, and in the fed state plasma concentrations stay below the limit of quantification — not reduced, unmeasurable [4]. At a 25 mg dose, a 71-week trial found 13.6% weight loss against 2.2% on placebo, with gastrointestinal adverse events in 74.0% of the drug group. That figure sits in the same range as the injectable trials, though the two cannot be subtracted from each other directly [5]. The full trial and the bioavailability science behind it are in what the pill actually does and what happens to the other 99%.
A third number, and a dose that is not what sellers mean
A separate oral semaglutide trial in 201 East Asian adults tested 50 mg daily. That is several times the 7 or 14 mg dose already approved for diabetes. It found 14.3% weight loss against 1.3% on placebo [6]. Mean starting weight in that trial was 91.9 kg, well below the roughly 113 kg typical of the large Western trials. The percentage comes off a smaller base, so it should not be set beside the others uncorrected. It matters mainly because of the dose: a storefront advertising "oral semaglutide" is almost never selling 50 mg. Compounded sellers frequently do not publish the milligram at all. The trial detail is in the 50 mg trial.
The list of conditions in phase 3 testing is worth reading as a commercial map: obstructive sleep apnea, hypertension, stress urinary incontinence, osteoarthritis pain and peripheral arterial disease. None is approved, and a trial running is not a result. It shows the strategy this class is pursuing: collecting indications that each unlock a different coverage pathway. That is how a drug excluded from weight-only reimbursement gets paid for anyway.
For a reader the practical question is what a daily tablet changes. Not efficacy, on current evidence. The pooled comparison in the network meta-analysis of nineteen drugs put orforglipron below tirzepatide and alongside injected semaglutide on weight. It also ranked among the highest for stopping because of side effects. What it changes is who will start — needles deter people — and how manufacturing scales, since a small molecule is not limited by peptide synthesis capacity. Whether that translates into lower prices is a separate question, examined in the ecnoglutide trial.